Sudden cardiac death in hyperthrophic cardiomyopathy: Comparison of predictive models

##plugins.themes.academic_pro.article.sidebar##

Published Feb 1, 2025
https://doi.org/10.62438/tunismed.v103i2.4779
Download
pdf
Vol. 103 No. 2 (2025): Tunis Med Feb 2025

##plugins.themes.academic_pro.article.main##

Mohamed Fehmi Bayar
Specialist in cardiology.
Emna Bennour
Cardiology Department, Abderrahmane Mami Hospital, Ariana, Tunisia.
Zied Ibn EL Hadj
Cardiology Department, Taher Maamouri Regional Hospital, Nabeul, Tunisia
Oumayma Zidi
Cardiology Department, Abderrahmane Mami Hospital, Ariana, Tunisia.
Afef Ben Hlima
Cardiology Department, Abderrahmane Mami Hospital, Ariana, Tunisia.
Ikram Kammoun
Cardiology Department, Abderrahmane Mami Hospital, Ariana, Tunisia.

Abstract

Introduction: Sudden cardiac death (SCD) risk stratification for primary prevention in patients with sarcomeric hypertrophic cardiomyopathy (HCM) has recently been reinforced by the establishment of a new model by the American College of Cardiology (ACC). This algorithm was characterized by a different approach compared to the previous HCM Risk Score.


Aim: The objective of this study was to compare risk stratification using both the European society of cardiology (ESC) and the ACC risk scores.


Methods: This was an observational, cohort-type prognostic study with retrospective data collection. Patients were classified according to their rhythmic risk estimated by both models and followed for a period of at least one year.


Results: Forty-seven patients were followed over a mean period of 32,4 months. The mean age of our patients was 55 years ± 14 years. We found a weak concordance between the two models (Kappa = 0.28). Four patients (9 %) presented arrhythmogenic events. The ACC algorithm indicated the implantation of an implantable cardioverter defibrillator (ICD) for these four patients whereas the HCM Risk Score indicated only two. The American algorithm had a better predictive potency with an area under the ROC curve of 0.785 compared to 0.654 with the HCM Risk Score with an NRI of 0.35. However, the number of ICDs to be implanted according to this algorithm was increased by 1.6 times.


Conclusion: The ACC algorithm was more efficient in detecting high-risk patients, but it considerably increased the number of ICDs indicated.

Keywords:

Hyperthrophic cardiomyopathy, Sudden cardiac death, Tachyarrhythmia

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet 2017;389(10075):1253-67.
  2. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020;76(25):3022-55.
  3. O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014;35(30):2010-20.
  4. Charron P. Rythmic risk scores and sudden cardiac death in hyperthrophic cardiomyopathy (article in French). La lettre du cardiologue 2021;545:32-6.
  5. O’Mahony C, Jichi F, Ommen SR, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation 2018;137(10):1015-23.
  6. Zegkos T, Tziomalos G, Parcharidou D, et al. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy. Hellenic J Cardiol 2022;63:15-21.
  7. Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol 2019;4(7):644-57.
  8. Nagueh SF, Phelan D, Abraham T, et al. Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr 2022;35(6):533-69.
  9. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1981;48(3):418–28.
  10. Candell-Riera J, Álvarez-Auñón A, Balda-Caravedo F, García del Castillo H, Soler-Soler J. Classification of hypertrophic cardiomyopathy using bidimensional echocardiography. Rev Esp Cardiol 1986;39(5):358–63.
  11. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35(39):2733-79.
  12. Caetano SJ, Sonpavde G, Pond GR. C-statistic: A brief explanation of its construction, interpretation and limitations. Eur J Cancer 2018;90:130-2.
  13. Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol 2010;106(10):1481-6.
  14. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009;119(13):1703-10.
  15. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42(5):873-9.
  16. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357(9254):420–4.
  17. Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H. Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 2011;17(6):459-64.
  18. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol 2017;69(7):761-73.
  19. Weng Z, Yao J, Chan RH, et al. Prognostic Value of LGE-CMR in HCM: A Meta- Analysis. JACC Cardiovasc Imaging 2016;9(12):1392-402.
  20. Webb J, Villa A, Bekri I, et al. Usefulness of Cardiac Magnetic Resonance Imaging to Measure Left Ventricular Wall Thickness for Determining Risk Scores for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2017;119(9):1450-5.
  21. Massera D, McClelland RL, Ambale-Venkatesh B, et al. Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA. J Am Heart Assoc 2019;8(8):e012250.
  22. Liu J, Wu G, Zhang C, et al. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy. Heart Rhythm 2020;17(10):1658-63.
  23. Freitas P, Ferreira AM, Arteaga-Fernández E, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson 2019;21(1):50.
  24. Mattos BPE, Scolari FL, Garbin HL. Discrepancy between International Guidelines on the Criteria for Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Arq Bras Cardiol 2020;115(2):197-204.
  25. Watkins H, MacRae C, Thierfelder L, et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 1993;3(4):333-7.
  26. Thierfelder L, MacRae C, Watkins H, et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A 1993;90(13):6270-4.
  27. Marian AJ. Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers. Clin Cardiol 1995;18(4):189-98.
  28. Marian AJ, Roberts R. Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998;9(1):88-99.
  29. Jaafar N, Girolami F, Zairi I, Kraiem S, Hammami M, Olivotto L. Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different? Glob Cardiol Sci Pract 2015;2015:16.
  30. Jaafar N, Gómez J, Kammoun I, et al. Spectrum of Mutations in Hypertrophic Cardiomyopathy Genes Among Tunisian Patients. Genet Test Mol Biomarkers 2016;20(11):674-9.
  31. Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130(6):484–95.
  32. Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol 2018;72(8):857–70.
  33. Dumont CA, Monserrat L, Soler R, et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 2007;60(1):15-23.
  34. Lee HJ, Kim HK, Lee SC, et al. Performance of 2020 AHA/ACC HCM Guidelines and Incremental Value of Myocardial Strain for Predicting SCD. JACC Asia 2023;4(1):10-22.
  35. Pan JA. Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy: Is There More to it Than Size? JACC Cardiovasc Imaging 2024;17(5):498-500.
  36. Zhao K, Zhu Y, Chen X, et al. Machine Learning in Hypertrophic Cardiomyopathy: Nonlinear Model From Clinical and CMR Features Predicting Cardiovascular Events. JACC Cardiovasc Imaging 2024;17(8):880-893.